Advicenne: distribution agreement for Southern Europe
Under the terms of the agreement, SPA is granted exclusive marketing rights for Sibnayal in its current therapeutic indication and in potential new indications, in territories covering southern Europe.
In return, Advicenne - which will remain the holder of the marketing authorization - will receive the proceeds from the sale of Sibnayal in the form of a transfer price and royalties for a combined amount significantly higher than 50% of future sales.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction